このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Guard Therapeutics International 将来の成長

Future 基準チェック /16

Guard Therapeutics Internationalの収益は年間6.3%で減少すると予測されていますが、年間収益は年間133.7%で増加すると予測されています。EPS は年間増加すると予測されています。自己資本利益率は 3 年後に146.6% 86.1%なると予測されています。

主要情報

-9.0%

収益成長率

97.8%

EPS成長率

Biotechs 収益成長	35.7%
収益成長率	149.0%
将来の株主資本利益率	147.9%
アナリストカバレッジ	Low
最終更新日	23 Aug 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

DB:5LH0 - アナリストの将来予測と過去の財務データ ( )SEK Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	299	N/A	N/A	N/A	1
12/31/2025	N/A	-91	-91	-91	1
12/31/2024	N/A	-86	-101	-101	1
6/30/2024	N/A	-79	-81	-81	N/A
3/31/2024	N/A	-88	-101	-101	N/A
12/31/2023	N/A	-113	-116	-116	N/A
9/30/2023	N/A	-137	-133	-133	N/A
6/30/2023	N/A	-146	-138	-138	N/A
3/31/2023	N/A	-134	-120	-120	N/A
12/31/2022	N/A	-113	-102	-102	N/A
9/30/2022	N/A	-95	-93	-93	N/A
6/30/2022	N/A	-97	-93	-93	N/A
3/31/2022	N/A	-88	-86	-86	N/A
12/31/2021	N/A	-82	-78	-78	N/A
9/30/2021	N/A	-69	-63	-63	N/A
6/30/2021	N/A	-47	-43	-43	N/A
3/31/2021	N/A	-44	-40	-40	N/A
12/31/2020	N/A	-40	-38	-38	N/A
9/30/2020	N/A	-43	-36	-37	N/A
6/30/2020	N/A	-39	-38	-38	N/A
3/31/2020	N/A	-41	-39	-39	N/A
12/31/2019	N/A	-45	-60	-60	N/A
9/30/2019	N/A	-73	-65	-66	N/A
6/30/2019	N/A	-82	-65	-66	N/A
3/31/2019	N/A	-86	-78	-78	N/A
12/31/2018	N/A	-87	-58	-58	N/A
9/30/2018	N/A	-61	-59	-58	N/A
6/30/2018	N/A	-63	-61	-59	N/A
3/31/2018	N/A	-67	N/A	-70	N/A
12/31/2017	N/A	-68	N/A	-66	N/A
9/30/2017	N/A	-72	N/A	-72	N/A
6/30/2017	N/A	-68	N/A	-68	N/A
3/31/2017	N/A	-61	N/A	-43	N/A
12/31/2016	N/A	-52	N/A	-47	N/A
9/30/2016	N/A	-43	N/A	-35	N/A
6/30/2016	N/A	-35	N/A	-34	N/A
3/31/2016	N/A	-32	N/A	-35	N/A
12/31/2015	N/A	-30	N/A	-27	N/A
9/30/2015	N/A	-23	N/A	-24	N/A
6/30/2015	0	-20	N/A	-18	N/A
3/31/2015	0	-15	N/A	-14	N/A
12/31/2014	0	-14	N/A	-15	N/A
9/30/2014	2	-12	N/A	-10	N/A
6/30/2014	5	-9	N/A	-8	N/A
3/31/2014	7	-7	N/A	-4	N/A
12/31/2013	8	-5	N/A	-3	N/A
9/30/2013	8	-4	N/A	-4	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 5LH0今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: 5LH0今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: 5LH0今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: 5LH0来年は収益がないと予測されています。

高い収益成長: 5LH0来年は収益がないと予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 5LH0の自己資本利益率は、3年後には非常に高くなると予測されています ( 146.6 %)。

Guard Therapeutics International 将来の成長

Future 基準チェック /16

主要情報

今後の成長に関する最新情報

No longer forecast to breakeven

No longer forecast to breakeven

No longer forecast to breakeven

No longer forecast to breakeven

Forecast to breakeven in 2024

Recent updates

First Patient Dosed in Guard Therapeutics' Phase 2B Study POINTER

New major risk - Financial position

Guard Therapeutics Receives Regulatory EU Approvals to Include Patients in its Phase 2b Study POInter

New minor risk - Shareholder dilution

New major risk - Revenue and earnings growth

No longer forecast to breakeven

New major risk - Financial position

New major risk - Revenue and earnings growth

Guard Therapeutics Reports Robust Efficacy of RMC-035 in Phase 2 (Akita) and Advances Clinical Development Program

New major risk - Revenue and earnings growth

Guard Therapeutics International AB Announces Completion of Clinical Phase 2 Study AKITA

Guard Therapeutics Announces the Full Results from the Phase 1B Clinical Study of the Investigational Drug RMC-035 in Patients Undergoing Kidney Transplantation

No longer forecast to breakeven

No longer forecast to breakeven

No longer forecast to breakeven

Guard Therapeutics Announces First Patient in US Dosed with Study Drug in the Ongoing Global Phase 2 Clinical Trial AKITA

Guard Therapeutics International AB (Publ) Announces 134 of the Planned 268 Patients Have Been Dosed in the Global Randomized, Double-Blinded and Placebo-Controlled Phase 2 Clinical Trial

Guard Therapeutics International AB (publ) Receives FDA Fast Track Designation for RMC-035

Guard Therapeutics International AB (publ) Receives IND Approval from the FDA for RMC-035

Guard Therapeutics Announces That the First Patient Has Been Dosed in A Phase 1b Clinical Trial of the Investigational Drug RMC-035 (ROSgard) in Kidney Transplantation

Guard Therapeutics Announces That the First Patient Has Been Dosed in A Phase 1b Clinical Trial of the Investigational Drug RMC-035 (ROSgard) in Kidney Transplantation

Guard Therapeutics Receives Approval from the Swedish Medical Products Agency to Conduct A Clinical Study of RMC-035 in Kidney Transplantation

High number of new and inexperienced directors

Guard Therapeutics International AB (publ) Appoints Torbjörn Larsson as Head of CMC (Chemistry, Manufacturing and Controls), Effective 1 May 2022

Guard Therapeutics International AB (publ) Provides In-Depth Information on Phase 2 Clinical Trial

Guard Therapeutics Announces First Patient Has Been Dosed in Guard Therapeutics' Phase 2 Clinical Trial of ROSgard

Forecast to breakeven in 2024

Chief Executive Officer recently bought €155k worth of stock

Guard Therapeutics Receives Approval to Expand the Global Phase 2 Study of Rosgard to Canada

Guard Therapeutics’ Application to Conduct a Phase 2 Clinical Trial of ROSgard is Approved by the German Medicines Regulator

Guard Therapeutics International AB (Publ) Reports Positive Results from Preclinical Studies

Guard Therapeutics appoints Sara Thuresson as Head of Clinical Operations

Guard Therapeutics International AB (Publ) Completes Pre-IND meeting with FDA

Guard Therapeutics Appoints Ann-Kristin Myde as Head of Global Project Management, Effective 1 April 2021

Guard Therapeutics Reports Positive Top-Line Results from Phase 1 Study of Rosgard in Individuals with Renal Impairment

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘